SHR-4849
Phase 2Small molecule
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-4849 is one of 61 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Paraplatin
AAvyxa
Phase 2
Beyfortus
BeiGenePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Erbitux
IImclone
Phase 2
Braftovi
PfizerPhase 2
Libtayo
RegeneronPhase 2
Sutent
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-4849. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details